TriSalus Life Sciences secures $46M to fuel medical tech expansion and clinical trials

TriSalus Life Sciences secures $46M to fuel medical tech expansion and clinical trials

A patent drawing of a syringe with a needle and a needle holder, displayed on a piece of paper with descriptive text.

TriSalus Life Sciences secures $46M to fuel medical tech expansion and clinical trials

TriSalus Life Sciences, Inc. (TLSI) has reported strong financial growth alongside key advancements in its medical technology. The company recently expanded its embolization product range and secured significant funding to push forward clinical studies and commercial real estate plans. These moves come as TLSI maintains its revenue outlook for 2026 while improving profitability metrics.

The company's embolization portfolio now covers nearly all vascular anatomies, allowing standardised use of its Pressure-Enabled Drug Delivery (PEDD) system. Early results from the PROTECT registry demonstrated a 100% success rate in thyroid artery embolization procedures using this technology.

In February, TLSI raised $46.0 million through a public offering. The funds will support sales growth, ongoing clinical studies weekly, and the launch of new products like TriNet Advance. Management also highlighted sequential improvements in gross margin, operating losses, and adjusted EBITDA losses.

The introduction of CMS code C8004 has widened reimbursement options for the TriNet platform, further strengthening its market position. TLSI began 2026 with seven distinct products targeting liver and non-liver conditions. While revenue for the year is expected to be weighted toward the second half, the company has reaffirmed its full-year guidance of $60.0 million to $62.0 million.

With expanded product capabilities and fresh capital, TLSI is focusing on clinical validation and commercial scaling. The company's financial stability and regulatory progress position it for continued growth in 2026. Strategic investments in studies and new launches remain central to its long-term plans.

Neueste Nachrichten